- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01953783
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
- 18 years or older
- Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence
- Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence
- Voluntary written consent
- Suitable venous access for the conduct of blood sampling
- Recovered from the reversible effects of prior anticancer therapy
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
- Female participants who are lactating or breastfeeding or have a positive serum pregnancy test
- Serious medical or psychiatric illness that could interfere with the study
- Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug
- Peripheral neuropathy greater than (>) Grade 2
- Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug
- Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
- Ongoing treatment with corticosteroids
- Major surgery within the 14 days preceding the first dose of study drug
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug
- Life-threatening illness unrelated to cancer
- Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive
- Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Any cardiovascular condition specified in the study protocol
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB
- History of urinary and/or fecal incontinence
- Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: IXAZOMIB
Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit. Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity. |
Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
Part A: Cmax: Maximum Observed Plasma Concentration of TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Cmax for TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine
Tijdsspanne: Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose.
|
Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine
Tijdsspanne: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Renal Clearance of Ixazomib
Tijdsspanne: Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve.
|
Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma
Tijdsspanne: Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as "percent of total radioactivity in plasma" with measure type as "number" and measure dispersion as "Not applicable, NA".
|
Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Urine
Tijdsspanne: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Feces
Tijdsspanne: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values
Tijdsspanne: Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Vital Signs
Tijdsspanne: Baseline up to Cycle 5 Day 25
|
Vital signs included oral body temperature, heart rate, and blood pressure.
|
Baseline up to Cycle 5 Day 25
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- C16016
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op IXAZOMIB
-
SCRI Development Innovations, LLCMillennium Pharmaceuticals, Inc.VoltooidMultipel myeloomVerenigde Staten
-
Millennium Pharmaceuticals, Inc.VoltooidGeavanceerde solide tumoren | Hematologische maligniteitenVerenigde Staten
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.WervingRelapsing Remitting Multiple Sclerose | Primaire progressieve multiple sclerose | Secundaire progressieve multiple scleroseVerenigd Koninkrijk
-
Millennium Pharmaceuticals, Inc.Voltooid
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation en andere medewerkersWervingRecidiverend refractair multipel myeloomVerenigde Staten
-
TakedaActief, niet wervendMultipel myeloom | Autologe stamceltransplantatieVerenigde Staten, Spanje, Australië, Tsjechië, Hongarije, Taiwan, Italië, Denemarken, Portugal, Singapore, Israël, Canada, Frankrijk, België, Verenigd Koninkrijk, Duitsland, Japan, Oostenrijk, Nederland, Korea, republiek van, Polen, Griekenla... en meer
-
University Hospital, CaenWervingMultipel myeloomFrankrijk
-
Millennium Pharmaceuticals, Inc.Voltooid
-
Ho Sup LeeTakedaWervingMantelcellymfoomKorea, republiek van
-
PfizerVoltooidGeavanceerde solide tumorenVerenigde Staten